

Special Issue

Recent Scientific Advances in Vaccination against Ebola and Marburg Virus Diseases

Message from the Guest Editor

The Ebola and Marburg virus diseases are severe haemorrhagic fevers affecting people and non-human primates (NHP) with a high case fatality rate. Due to climate and environmental change leading to increasing interactions between humans and wildlife hosts, EVD and MVD outbreaks could become more frequent. It is therefore extremely important to develop and reinforce prevention and control strategies in at-risk countries to limit the extent of current and future outbreaks.

Vaccines play a key role in the response to epidemic threats and have been an important part of the response to EVD outbreaks due to *Zaire ebolavirus* since the 2014–16 West African outbreak. There are no licensed vaccines against Sudan and Marburg virus, although several candidates are under development. This Special Issue aims to collect recent scientific knowledge and advances in vaccination against Ebola and Marburg virus diseases. We are interested in a broad area of research, including clinical trials, vaccine roll-out strategies, mathematical modelling, NHP studies and literature reviews, which can inform future vaccination strategies against EVD and MVD.

Guest Editor

Dr. Daniela Manno

Department of Nutrition and Public Health Intervention Research,
London School of Hygiene and Tropical Medicine (LSHTM), Keppel
Street, London WC1E 7HT, UK

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/154780

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).